- 2022-11-16 21:18:38
- 89
Our YBODY® platform is a BsAb platform that focuses on the development of asymmetric human immunoglobulin G (IgG)-like BsAbs with the structure of single-chain variable fragment – antigen-binding fragment – crystallizable fragment (scFv-Fab-Fc structure). The BsAbs with scFv-Fab-Fc structure developed by the YBODY® platform have unique features, such as a favorable safety profile and the reduced affinity to human immune cells, reaching a product purity of 99%, minimizing mispairing of the heavy chain and light chain of a BsAb, favorable PK/PD profile and high stability. Based on YBODY® platform, YZYBIO has developed three T cell-engaging BsAbs, namely M701, M802 and Y150. Y150 is the only CD38-targeting and T cell engager BsAb that has entered into clinical development in China as of the latest practicable date.
